ADMA Biologics, Inc. (ADMA) is a bio-pharmaceutical organization dedicated to manufacturing, developing and marketing specialized plasma-derived biologics for the treatment of immune deficiencies and the prevention of specified infectious diseases. The company was founded in 2004 and has its headquarters based in Ramsey, New Jersey, United States. ADMA Biologics' mission is to improve the health and quality of life of patients suffering from immunological disorders.
ADMA's extensive product portfolio includes some FDA-approved immunoglobulin products for patients facing immune system challenges. ADMA's flagship product BIVIGAM® is an intravenous immune globulin which was accepted by the U.S. Food and Drug Administration (FDA) in 2019 for patients with primary humoral immunodeficiency (PIDD).
This serious and chronic disease involves weakening of the immune system, causing susceptibility to infections. Another significant product from the company is ASCENIV™, an intravenous immune globulin for treating PIDD patients. Notably, ADMA also offers NABI-HB®, useful in protecting against Hepatitis B infections.
ADMA owns and operates three FDA-approved plasma collection centers under the ADMA BioCenters brand. These centers contribute to enhancing the company's control over plasma supply, a crucial raw material for its products. In addition to its own plasma collection, ADMA also maintains strategic relationships with third-party suppliers.
The company also operates its ImmunoTek plasma collection facilities, which provide high-quality plasma that is processed into life-saving immunoglobulin and other plasma-derived products. ADMA's commitment to plasma collection supports the industry's overall safety and supply chain by ensuring continued availability of this critical resource.
What sets ADMA Biologics apart is its high-value platform of plasma assets and immunoglobulin therapy, which helps in maintaining, restoring, and enhancing the health of patients. Moreover, the executives at ADMA possess extensive experience in plasma and immunoglobulin science and commercialization, thus allowing the company to continuously contribute to scientific advancement in the field.
Alongside capturing opportunities in the US market, ADMA Biologics is keen to expand its products' global presence. It believes that its comprehensive patient-centric approach, which commands a strong balance between innovative biologics and traditional patient care, will aid in providing personalized treatment solutions to a larger consumer base worldwide.
In terms of commitment to research and development, ADMA continues to invest heavily in expanding its clinical indications and advancing the plasma-processing sector. The company’s ethos embraces a steadfast approach to innovation, consumer safety, and health care cost containment that contributes to a sustainable healthcare system.
Overall, ADMA Biologics, Inc. remains a trusted provider in the healthcare industry, continuously striving to explore and implement therapeutic possibilities to aid the fight against immune deficiencies and infectious diseases around the globe.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes Adma Biologics Inc (NASDAQ: ADMA) price dynamics, highlighting a near-term positive sentiment that may shift and a broader weak alignment. It identifies an exceptional risk-reward short setup with a 26.5% downside target and outlines three AI-generated institutional trading strategies for different risk profiles. The analysis also provides multi-timeframe signal insights, including support and resistance levels for near-term, mid-term, and long-term horizons.
Adma Biologics (ADMA) experienced a significant drop in its stock price, falling 1.01% at the latest close, underperforming major market indices like the S&P 500, Dow, and Nasdaq. The company is projected to report strong earnings and revenue growth for its upcoming release and the full fiscal year, with positive analyst estimate revisions suggesting a favorable business outlook. Despite a Zacks Rank of #3 (Hold), its Forward P/E ratio indicates a discount compared to its industry average within the Medical - Biomedical and Genetics sector.
This article from Stock Traders Daily discusses the volatility of Adma Biologics Inc (NASDAQ: ADMA), highlighting a mid-channel oscillation pattern and a significant risk-reward short setup. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with a multi-timeframe signal analysis, indicating neutral to weak sentiment across different horizons. The piece emphasizes the platform's AI models for optimizing position sizing and managing risk for investors.
ADMA Biologics (ADMA) reported strong Q2 2026 results with $124.4 million in sales and $37.82 million in net income, reaffirming full-year revenue guidance. Despite a year-to-date share price drop, the stock has seen positive short-term returns and a significant 5-year total shareholder return. Analysts believe the company is 46% undervalued with a fair value of $17.60, contingent on successful execution and avoiding setbacks.
Bank of America Corp DE significantly increased its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 107.5% in the first quarter, now owning 3.998 million shares valued at $36 million. Other institutional investors like Sachem Head, Westfield Capital, and Capital Research also raised their holdings, contributing to the high institutional ownership of 75.68%. While analyst sentiment is mixed with a "Hold" rating and a consensus price target of $18.67, ADMA Biologics matched its quarterly EPS estimates and reported a 2% year-over-year revenue increase.
ADMA Biologics reaffirmed its full-year 2026 revenue guidance of US$530 million to US$560 million after reporting solid Q2 2026 results. The company's performance, including higher quarterly and year-to-date EPS, indicates management confidence despite a previous, more bullish guidance reset. The article highlights the importance of production scaling, yield efficiency, and plasma availability to ADMA's investment narrative, which projects significant revenue and earnings growth by 2029.